Showing results (11-20 of 147) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|July 23, 2022
Non-relapse cytopenias following allogeneic stem cell transplantation, a case based reviewAshvind Prabahran, Rachel Koldej, Lynette Chee, et al.
International Journal of Molecular Sciences|February 13, 2025
Preimplantation Genetic Testing (PGT) to Reduce the Risk for GBA-Related Parkinson's Disease: Expanding the Applications for Embryo SelectionShachar Zuckerman, Ari Zimran, Jeff Szer, et al.
Internal Medicine Journal|May 21, 2025
Hyperuricaemia in type 1 Gaucher disease: is uric acid a biomarker for disease severity?Zufit Hexner-Erlichman, Salmas Watad, Jeff Szer, et al.
Bone Marrow Transplantation|June 16, 2018
Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantationEric Wong, Joanne E Davis, Andrew Grigg, et al.
Internal Medicine Journal|June 28, 2022
Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher diseaseCalvin Gan, Patricia L Robertson, Jeffrey K C Lai, et al.
Cancer|February 22, 2002
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphomaJohn F Seymour, Andrew P Grigg, Jeff Szer, et al.
Blood Cells, Molecules & Diseases|February 12, 2017
Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experienceJeffrey K C Lai, Patricia L Robertson, Christine Goh, et al.
Internal Medicine Journal|November 19, 2021
Oromandibular parafunction in chronic graft-versus-host disease: novel association and treatment approachPurwa Joshi, Lynette Kiers, Andrew Evans, et al.
Frontiers in Immunology|November 3, 2025
Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher diseaseJinyun Zou, Tahereh Noori, Mark Walterfang, et al.
International Journal of Molecular Sciences|April 13, 2023
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction TherapyMajdolen Istaiti, Dafna Frydman, Tama Dinur, et al.
Pageof 15